Neurodegeneration Biomarkers for Diagnosis of Alzheimer’s and MND

Neurology July 26, 2017 at 8:57 AM 0 comments

EUROIMMUN Press Release 26 July, 2017 – A portfolio of CSF biomarkers corresponding to different stages of the neurodegenerative process aids diagnosis of Alzheimer’s disease (AD) and motor neuron diseases (MND). The classic AD markers beta amyloid and tau measure aggregates like plaques and tangles. The most reliable measure ofRead More

Comprehensive Serological Diagnostics in Neurology

Neurology July 26, 2017 at 8:55 AM 0 comments

EUROIMMUN Press Release 26 July, 2017 – Neurological disorders, including memory deficits, psychosis and seizures, can be caused by underlying autoimmune reactions. In unexplained neurological cases, autoantibody testing can help establish a diagnosis of e.g. anti-NMDAR encephalitis, paraneoplastic syndrome (PNS) or neuromyelitis optica. EUROIMMUN has developed a comprehensive range of assaysRead More

ANTABIO Awarded Up to $8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chronic Infections in Cystic Fibrosis Patients

Respiratory July 25, 2017 at 2:21 PM 0 comments

Labège, France, 25 July, 2017 – Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-XRead More

Orchard Therapeutics Announces That OTL-101 Has Received a Rare Paediatric Disease Designation

Uncategorized July 24, 2017 at 5:14 PM 0 comments

London, UK, 24 July, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative autologous ex-vivo gene therapies to patients with rare diseases of high unmet medical need is delighted to announce today that the US Food and Drug Administration (FDA) granted a Rare Paediatric DiseaseRead More

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

Gastroenterology, Oncology July 18, 2017 at 9:41 AM 0 comments

Top-line results are expected in September 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D),with a primary endpoint of response in stool consistency as compared to baseline IBS is oneRead More

Introducing EMJ Nephrology 5.1

Introducing EMJ Nephrology 5.1

Nephrology July 18, 2017 at 9:05 AM 0 comments

United Kingdom, July 18, 2017: Welcome to the latest edition of EMJ Nephrology. This instalment presents a complete review of the incredibly successful ERA-EDTA Congress 2017, which this year was held in Madrid, Spain. Speakers from >100 countries were in attendance to share their knowledge in the form of lectures,Read More

RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

Uncategorized July 12, 2017 at 4:58 PM 0 comments

The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn’s disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects who have completed week 26Read More

Abu Dhabi Health Show Comes to London

Uncategorized July 12, 2017 at 4:53 PM 0 comments

London, UK, 12 July, 2017 – Pri-Med Global is to re-brand its healthcare event into Future Healthcare UK, international exhibition and conference. The initial show was launched in May 2017 and leveraged partnerships with many influential organisations, both in the UK and around the world. An unprecedented response to the launchRead More

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer

Oncology July 12, 2017 at 11:59 AM 0 comments

Oncotype DX® test endorsed for guiding treatment decisions on adjuvant chemotherapy both in node-negative and in node-positive disease Gene expression signatures recommended for the first time as preferable to standard pathology, when adequate reproducibility is not granted Geneva, Switzerland, 12 July, 2017 – Genomic Health today announced that the 15thRead More

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

Oncology July 11, 2017 at 4:39 PM 0 comments

ASCO recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive early-stage breast cancer patients Revised ASCO Guidelines mark the fourth positiveRead More